Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Royalty Pharma plc

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEW YORK, NOV. 26, 2025 (GLOBE NEWSWIRE) -- ROYALTY PHARMA PLC (NASDAQ: RPRX) TODAY ANNOUNCED THAT IT WILL PARTICIPATE IN THE FOLLOWING UPCOMING INVESTOR CONFERENCES DURING THE MONTH OF DECEMBER:

ROYALTY PHARMA TO PRESENT AT UPCOMING INVESTOR CONFERENCES

PORTFOLIO RECEIPTS GROWTH OF 11% TO $814 MILLION; ROYALTY RECEIPTS GROWTH OF 11% NET CASH PROVIDED BY OPERATING ACTIVITIES OF $703 MILLION RAISED FULL YEAR 2025 GUIDANCE: PORTFOLIO RECEIPTS EXPECTED TO BE $3,200 TO $3,250 MILLION NEW YORK, NOV. 05, 2025 (GLOBE NEWSWIRE) -- ROYALTY PHARMA PLC (NASDAQ: RPRX) TODAY REPORTED FINANCIAL RESULTS FOR THE THIRD QUARTER OF 2025 AND RAISED FULL YEAR 2025 GUIDANCE FOR PORTFOLIO RECEIPTS. WE DELIVERED STRONG THIRD QUARTER 2025 RESULTS, RAISED OUR FULL YEAR GUIDANCE AND ARE ON TRACK TO DELIVER ANOTHER YEAR OF DOUBLE-DIGIT TOP-LINE GROWTH, SAID PABLO LEGORRETA, ROYALTY PHARMA'S FOUNDER AND CHIEF EXECUTIVE OFFICER.

ROYALTY PHARMA REPORTS THIRD QUARTER 2025 RESULTS

NEW YORK AND CAMBRIDGE, MASS., NOV. 04, 2025 (GLOBE NEWSWIRE) -- ROYALTY PHARMA PLC (NASDAQ: RPRX) TODAY ANNOUNCED THAT IT HAS ACQUIRED A ROYALTY INTEREST IN ALNYLAM'S AMVUTTRA FROM FUNDS MANAGED BY BLACKSTONE LIFE SCIENCES (BLACKSTONE) FOR $310 MILLION. THE ROYALTY INTEREST BEING SOLD STEMS FROM BLACKSTONE'S 2020 FINANCING COLLABORATION WITH ALNYLAM , IN WHICH BLACKSTONE INVESTED TO SUPPORT AMVUTTRA'S PIVOTAL PHASE 3 HELIOS-B TRIAL.

ROYALTY PHARMA ACQUIRES ROYALTY INTEREST IN ALNYLAM'S AMVUTTRA FOR $310 MILLION FROM BLACKSTONE LIFE SCIENCES

NEW YORK, OCT. 17, 2025 (GLOBE NEWSWIRE) -- THE BOARD OF DIRECTORS OF ROYALTY PHARMA PLC (NASDAQ: RPRX) HAS APPROVED THE PAYMENT OF A DIVIDEND FOR THE FOURTH QUARTER OF 2025 OF $0.22 PER CLASS A ORDINARY SHARE.

ROYALTY PHARMA DECLARES FOURTH QUARTER 2025 DIVIDEND

NEW YORK, OCT. 09, 2025 (GLOBE NEWSWIRE) -- ROYALTY PHARMA PLC (NASDAQ: RPRX) TODAY ANNOUNCED THAT IT WILL REPORT ITS THIRD QUARTER 2025 FINANCIAL RESULTS ON WEDNESDAY, NOVEMBER 5, 2025 BEFORE THE U.S. FINANCIAL MARKETS OPEN. THE COMPANY WILL HOST A CONFERENCE CALL AND SIMULTANEOUS WEBCAST AT 8:00 A.M. EASTERN TIME THAT DAY.

ROYALTY PHARMA TO ANNOUNCE THIRD QUARTER 2025 FINANCIAL RESULTS ON NOVEMBER 5, 2025

NEW YORK, SEPT. 29, 2025 (GLOBE NEWSWIRE) -- ROYALTY PHARMA PLC (NASDAQ: RPRX) TODAY ANNOUNCED THAT THE INDEPENDENT DIRECTORS OF THE BOARD HAVE UNANIMOUSLY APPOINTED DR. TED W. LOVE, AN INDEPENDENT DIRECTOR SINCE 2020, AS LEAD INDEPENDENT DIRECTOR. DR. LOVE WILL CONTINUE TO CHAIR THE NOMINATING AND CORPORATE GOVERNANCE COMMITTEE.

ROYALTY PHARMA APPOINTS DR. TED W. LOVE AS LEAD INDEPENDENT DIRECTOR

NEW YORK, SEPT. 19, 2025 (GLOBE NEWSWIRE) -- ROYALTY PHARMA PLC (NASDAQ: RPRX) TODAY ANNOUNCED THAT IT WILL PARTICIPATE IN A FIRESIDE CHAT AT BERNSTEIN'S 2ND ANNUAL HEALTHCARE FORUM ON TUESDAY, SEPTEMBER 23, 2025 AT 2:50 P.M. ET.

ROYALTY PHARMA TO PRESENT AT BERNSTEIN'S 2ND ANNUAL HEALTHCARE FORUM

ON TRACK TO DELIVER PORTFOLIO RECEIPTS OF $4.7 BILLION OR MORE BY 2030, SIGNIFICANTLY AHEAD OF CONSENSUS GOAL TO ACHIEVE AT LEAST MID-TEENS AVERAGE ANNUAL TOTAL SHAREHOLDER RETURN OVER NEXT 5 YEARS WITH SIGNIFICANT UPSIDE POTENTIAL FROM RECOGNITION FOR ROYALTY PHARMA'S PLATFORM VALUE INVESTMENTS SINCE 2020 ON TRACK TO DELIVER MID-TEENS UNLEVERED IRR, AHEAD OF TARGET ACHIEVED 15% RETURN ON INVESTED CAPITAL (ROIC) AND 21% RETURN ON INVESTED EQUITY (ROIE) SINCE 2019 ROYALTY MARKET CONTINUES TO GROW RAPIDLY, DOUBLING OVER FIVE YEARS SINCE ROYALTY PHARMA'S 2020 IPO STRONG INDUSTRY TAILWINDS AND DEMAND FOR ROYALTY FUNDING SUPPORTED BY DELOITTE MARKET STUDY REPORT NEW YORK, SEPT. 11, 2025 (GLOBE NEWSWIRE) -- ROYALTY PHARMA PLC (NASDAQ: RPRX) WILL HOST AN INVESTOR DAY IN NEW YORK CITY TODAY.

ROYALTY PHARMA INVESTOR DAY HIGHLIGHTS STRONG GROWTH OUTLOOK AND COMPANY'S PLANS TO DRIVE VALUE CREATION

NEW YORK, SEPT. 10, 2025 (GLOBE NEWSWIRE) -- ROYALTY PHARMA PLC (NASDAQ: RPRX) TODAY ANNOUNCED THE RELEASE OF A BIOPHARMA ROYALTY MARKET STUDY CONDUCTED BY DELOITTE. THE REPORT, TITLED "ROLE OF ROYALTIES IN FUNDING BIOPHARMA INNOVATION," IS THE FIRST OF ITS KIND AND OFFERS A COMPREHENSIVE ANALYSIS OF THE CURRENT DYNAMICS, GROWTH DRIVERS AND OUTLOOK FOR BIOPHARMA ROYALTIES. THE FULL REPORT IS AVAILABLE FOR DOWNLOAD AT DELOITTE'S WEBSITE AND ROYALTY PHARMA'S WEBSITE.

ROYALTY PHARMA ANNOUNCES RELEASE OF DELOITTE'S REPORT ON THE BIOPHARMA ROYALTY MARKET

NEW YORK, SEPT. 04, 2025 (GLOBE NEWSWIRE) -- ROYALTY PHARMA PLC (NASDAQ: RPRX) TODAY ANNOUNCED THAT IT WILL PARTICIPATE IN A FIRESIDE CHAT AT THE MORGAN STANLEY 23RD ANNUAL GLOBAL HEALTHCARE CONFERENCE ON TUESDAY, SEPTEMBER 9, 2025 AT 3:20 P.M. ET.

ROYALTY PHARMA TO PRESENT AT THE MORGAN STANLEY 23RD ANNUAL GLOBAL HEALTHCARE CONFERENCE

NEW YORK, SEPT. 02, 2025 (GLOBE NEWSWIRE) -- ROYALTY PHARMA PLC (NASDAQ: RPRX) ANNOUNCED TODAY THAT IT HAS PRICED AN OFFERING OF $2.0 BILLION OF SENIOR UNSECURED NOTES, COMPRISED OF THE FOLLOWING (COLLECTIVELY, THE NOTES):

Royalty Pharma plc

RPRX

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Royalty Pharma plc

RPRX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

RPRX